FCHO2 and diffuse large B-cell lymphoma: In their study, Chen et al. demonstrated that CD3G, CD3D, GNB4, FCHO2, and GPR183 are involved in regulation of the immune microenvironment in DLBCL and can be used as biomarkers for predicting immunochemotherapy response as well as for potential therapeutic applications in DLBCL patients [10].